Milnacipran: a unique antidepressant?

Kasper, Siegfried; Pail, G.

doi:10.2147/ndt.s11777

Cited by 15 publications

(11 citation statements)

References 52 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A relationship exists between the different neurotransmitter deficits and the symptoms of major depressive disorder21 (Figure 1). Agitation, loss of appetite, decreased libido, suicidal ideation, aggressive behavior (verbal or physical), and irritability are symptoms related principally to the dysfunction of serotonergic neurotransmission 21,22. Decreased concentration, mental and physical slowing, loss of energy, lassitude, tiredness, and reduced self-care (hygiene) are symptoms related principally to reduced noradrenergic activity 21,22.…”

Section: Mechanisms Underlying Social Dysfunction In Depressed Patientsmentioning

confidence: 99%

“…Agitation, loss of appetite, decreased libido, suicidal ideation, aggressive behavior (verbal or physical), and irritability are symptoms related principally to the dysfunction of serotonergic neurotransmission 21,22. Decreased concentration, mental and physical slowing, loss of energy, lassitude, tiredness, and reduced self-care (hygiene) are symptoms related principally to reduced noradrenergic activity 21,22. Depressed mood, loss of interest or pleasure, sleep disturbances, feeling of worthlessness, pessimism, and anxiety are symptoms related to changes in both 5-HT and NE neurotransmission 21,22…”

Section: Mechanisms Underlying Social Dysfunction In Depressed Patientsmentioning

confidence: 99%

“…Decreased concentration, mental and physical slowing, loss of energy, lassitude, tiredness, and reduced self-care (hygiene) are symptoms related principally to reduced noradrenergic activity 21,22. Depressed mood, loss of interest or pleasure, sleep disturbances, feeling of worthlessness, pessimism, and anxiety are symptoms related to changes in both 5-HT and NE neurotransmission 21,22…”

Section: Mechanisms Underlying Social Dysfunction In Depressed Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors

Briley¹,

Moret²

2010

NDT

Self Cite

View full text Add to dashboard Cite

Depression is a disabling condition resulting in significant impairment in social functioning, involving the patient’s family, friends, work colleagues, and society at large. Although both psychologic and pharmacologic treatments generally improve many depressive symptoms, they do not always result in significant improvement in social functioning. The importance of recovery of social functioning in depressed patients is now widely appreciated, and studies are beginning to include it in evaluations of therapeutic efficacy. Among the various social adjustment evaluation rating scales, the Social Adaptation Self-Evaluation Scale, a social motivation and behavior scale, has been found to be simple to use and sensitive to change. Using this scale, the selective norepinephrine reuptake inhibitor, reboxetine, has been shown to be significantly more effective in improving social functioning than the selective serotonin reuptake inhibitor, fluoxetine. These findings are consistent with the notion that improvement in social adaptation involves functions depending primarily on noradrenergic neurotransmission. This hypothesis suggests that the serotonin and norepinephrine reuptake inhibitors, venlafaxine, duloxetine, and milnacipran, could be particularly helpful in improving social functioning. Preliminary studies with the serotonin and norepinephrine reuptake inhibitors suggest that they significantly improve social functioning. Comparative studies with selective serotonin reuptake inhibitors on the effects on social functioning should be encouraged.

show abstract

Section: Mechanisms Underlying Social Dysfunction In Depressed Patientsmentioning

confidence: 99%

Section: Mechanisms Underlying Social Dysfunction In Depressed Patientsmentioning

confidence: 99%

Section: Mechanisms Underlying Social Dysfunction In Depressed Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors

Briley¹,

Moret²

2010

NDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…A relationship exists between the different neurotransmitter deficits and the symptoms of major depression 5. Depressed mood; loss of interest or pleasure; sleep disturbances; and feeling of worthlessness, pessimism, and anxiety are symptoms related to changes in both 5-HT and NE neurotransmission 5,6. Agitation, loss of appetite, decreased libido, suicidal ideation, aggressive behavior (verbal or physical), and irritability are symptoms related principally to the dysfunction of 5-HT neurotransmission 5,6.…”

Section: Introductionmentioning

confidence: 99%

“…DA is important in the regulation of drive 7,8. Reduced noradrenergic activity is responsible for decreased concentration, mental and physical slowing, loss of energy, lassitude, tiredness, and reduced self-care 5,6…”

Section: Introductionmentioning

confidence: 99%

Improvement of the noradrenergic symptom cluster following treatment with milnacipran

Kasper

Meshkat²,

Kutzelnigg³

2011

NDT

Self Cite

View full text Add to dashboard Cite

Depression has a major impact on social functioning. Decreased concentration, mental and physical slowing, loss of energy, lassitude, tiredness, and reduced self-care are all symptoms related to reduced noradrenergic activity. Depressed mood; loss of interest or pleasure; sleep disturbances; and feelings of worthlessness, pessimism, and anxiety are related to reduced activity of both serotonergic and noradrenergic neurotransmission. The importance of noradrenergic neurotransmission in social functioning is supported by studies with the specific norepinephrine reuptake inhibitor reboxetine. In healthy volunteers, reboxetine increases cooperative social behavior and social drive. A placebo-controlled study in depressed patients comparing reboxetine with the selective serotonin reuptake inhibitor (SSRI) fluoxetine showed significantly greater improvement in social adaptation with reboxetine. Two recent studies have examined the effect of the serotonin and norepinephrine reuptake inhibitor milnacipran on social adaptation. A study in depressed patients found that at the end of 8 weeks of treatment with milnacipran, 42.2% patients were in remission on the Social Adaptation Self-evaluation Scale (SASS). Another study in depressed workers or homemakers found that mean depression scores were significantly reduced after 2 weeks, whereas the SASS scores were significantly improved after 4 weeks. A preliminary study comparing depressed patients treated with milnacipran or the SSRI paroxetine showed that milnacipran treatment resulted in a greater number of patients in social remission. The available data thus suggest that milnacipran may improve social functioning, with a possibly greater effect than the SSRI paroxetine. These preliminary data suggest further evaluation of social dysfunction and its treatment outcome in future trials of milnacipran.

show abstract

Antidepressants and Anticonvulsants

Okafor

Aquino

2019

Academic Pain Medicine

View full text Add to dashboard Cite

Milnacipran: a unique antidepressant?

Cited by 15 publications

References 52 publications

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors

Improvement of the noradrenergic symptom cluster following treatment with milnacipran

Antidepressants and Anticonvulsants

Contact Info

Product

Resources

About